Mustang, Harvard partner on CRISPR CAR T therapies

Mustang Bio Inc. (NASDAQ:MBIO) partnered with Harvard University to develop CRISPR-Cas9-enhanced CAR T therapies targeting hematologic and solid tumor cancers.

The biotech in-licensed CRISPR-Cas9 gene editing technology from Harvard, as well as technology

Read the full 331 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE